LECT2 amyloidosis
LECT2 Amyloidosis

LECT2 amyloidosis is a form of amyloidosis characterized by the deposition of leukocyte cell-derived chemotaxin 2 (LECT2) protein in various tissues, leading to organ dysfunction. It is a rare condition that primarily affects the kidney, but can also involve other organs such as the liver and spleen.
Pathophysiology
LECT2 is a protein that is normally produced by the liver and plays a role in immune response and inflammation. In LECT2 amyloidosis, the LECT2 protein misfolds and aggregates into amyloid fibrils, which are deposited in tissues. This deposition disrupts normal tissue architecture and function, leading to organ damage.
Clinical Presentation
Patients with LECT2 amyloidosis often present with symptoms related to kidney dysfunction, such as proteinuria, edema, and hypertension. Some patients may also exhibit liver dysfunction or splenomegaly. The disease is often diagnosed in older adults and has been reported more frequently in individuals of Hispanic descent.
Diagnosis
The diagnosis of LECT2 amyloidosis is confirmed by biopsy of affected tissue, typically the kidney, showing amyloid deposits. These deposits are identified using Congo red staining, which reveals apple-green birefringence under polarized light. Immunohistochemistry or mass spectrometry can be used to specifically identify LECT2 as the amyloid protein.
Treatment
There is currently no specific treatment for LECT2 amyloidosis. Management focuses on controlling symptoms and complications, such as hypertension and chronic kidney disease. In some cases, kidney transplantation may be considered for patients with end-stage renal disease.
Prognosis
The prognosis of LECT2 amyloidosis varies depending on the extent of organ involvement and the patient's overall health. Kidney involvement often leads to progressive renal failure, which can significantly impact survival and quality of life.
Related Pages

See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian